Published in Clin Vaccine Immunol on September 04, 2013
Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis. MBio (2016) 1.01
Immunization with Pneumococcal Surface Protein K of Nonencapsulated Streptococcus pneumoniae Provides Protection in a Mouse Model of Colonization. Clin Vaccine Immunol (2015) 0.85
Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media. Int J Pediatr Otorhinolaryngol (2014) 0.83
Emergence of Multidrug-resistant Pneumococcal Serotype 35B among U.S. Children. J Clin Microbiol (2016) 0.79
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet (2009) 15.31
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis (2007) 6.45
Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol (2002) 6.03
Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol (1997) 4.78
A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A (2006) 4.40
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med (2009) 4.38
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell (2000) 3.19
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2010) 2.95
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J (1994) 2.73
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Diagnosis of bacteremic pneumococcal pneumonia by amplification of pneumolysin gene fragment in serum. J Infect Dis (1995) 2.62
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis (2000) 2.55
RrgA and RrgB are components of a multisubunit pilus encoded by the Streptococcus pneumoniae rlrA pathogenicity islet. Infect Immun (2006) 2.18
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol (2007) 2.01
PspC, a pneumococcal surface protein, binds human factor H. Infect Immun (2001) 1.92
Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem (2012) 1.90
Transcriptional regulation in the Streptococcus pneumoniae rlrA pathogenicity islet by RlrA. J Bacteriol (2003) 1.89
Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol (2006) 1.88
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene (2002) 1.87
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine (2000) 1.82
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun (2001) 1.62
Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol Infect (1993) 1.60
Acute pneumonia in Zimbabwe: bacterial isolates by lung aspiration. Arch Dis Child (1988) 1.56
Species-specific binding of human secretory component to SpsA protein of Streptococcus pneumoniae via a hexapeptide motif. Mol Microbiol (2000) 1.56
Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol (2007) 1.51
Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis (2008) 1.49
Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J Immunol (2004) 1.41
Pre-vaccination nasopharyngeal pneumococcal carriage in a Nigerian population: epidemiology and population biology. PLoS One (2012) 1.37
Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis (2001) 1.30
Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine (2012) 1.28
Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio (2012) 1.22
Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol (2006) 1.20
Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun (2003) 1.15
The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun (2002) 1.14
Development of an automated and multiplexed serotyping assay for Streptococcus pneumoniae. Clin Vaccine Immunol (2011) 1.13
Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine (2010) 1.12
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine (2011) 1.00
Invasive Streptococcus pneumoniae isolates from Argentinian children: serotypes, families of pneumococcal surface protein A (PspA) and genetic diversity. Epidemiol Infect (2004) 0.97
New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics (2009) 0.92
Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers. Clin Vaccine Immunol (2008) 0.91
PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vaccine Immunol (2012) 0.84
PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan. PLoS One (2013) 0.83
Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol (2007) 7.44
Genetic basis for the new pneumococcal serotype, 6C. Infect Immun (2007) 5.27
Basophils enhance immunological memory responses. Nat Immunol (2008) 3.35
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology (2009) 2.56
Validation of a multiplex pneumococcal serotyping assay with clinical samples. J Clin Microbiol (2006) 2.48
PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol (2008) 2.42
A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J Infect Dis (2010) 2.23
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol (2006) 2.20
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity (2007) 2.07
Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology (2009) 2.07
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol (2006) 2.00
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun (2004) 1.91
Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem (2012) 1.90
Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J (2010) 1.87
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Rapid multiplex assay for serotyping pneumococci with monoclonal and polyclonal antibodies. J Clin Microbiol (2005) 1.79
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS (2007) 1.70
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine (2011) 1.61
Rarely occurring 19A-like cps locus from a serotype 19F pneumococcal isolate indicates continued need of serology-based quality control for PCR-based serotype determinations. J Clin Microbiol (2009) 1.55
Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence. Infect Immun (2006) 1.55
Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol (2003) 1.54
Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun (2008) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect Immun (2003) 1.51
Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity (2002) 1.50
Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun (2010) 1.49
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am J Respir Cell Mol Biol (2007) 1.42
Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J Immunol (2007) 1.41
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol (2009) 1.38
The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J Immunol (2004) 1.37
Evolution and virulence of serogroup 6 pneumococci on a global scale. J Bacteriol (2002) 1.37
From Quellung to multiplex PCR, and back when needed, in pneumococcal serotyping. J Clin Microbiol (2012) 1.30
Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J Immunol (2009) 1.27
Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis (2005) 1.26
Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun (2007) 1.25
Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem (2013) 1.24
Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect Immun (2010) 1.23
Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio (2012) 1.22
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun (2005) 1.22
Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection from superoxide. Infect Immun (2004) 1.21
Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol (2006) 1.20
Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci U S A (2003) 1.19
Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun (2003) 1.19
Low-cost, high-throughput, automated counting of bacterial colonies. Cytometry A (2010) 1.18
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes. J Biol Chem (2008) 1.15
Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun (2003) 1.15
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis (2008) 1.14
Simplified method to automatically count bacterial colony forming unit. J Immunol Methods (2005) 1.14
The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun (2010) 1.14
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Nasopharyngeal pneumococcal carriage of children attending day care centers in Korea: comparison between children immunized with 7-valent pneumococcal conjugate vaccine and non-immunized. J Korean Med Sci (2011) 1.13
Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology (2012) 1.13
Development of an automated and multiplexed serotyping assay for Streptococcus pneumoniae. Clin Vaccine Immunol (2011) 1.13
"Dodgy 6As": differentiating pneumococcal serotype 6C from 6A by use of the Quellung reaction. J Clin Microbiol (2009) 1.11
Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol (2003) 1.10
Cross-reactivity of current serogroup 6 factor sera from Statens Serum Institut with the recently described pneumococcal serotype 6d. J Clin Microbiol (2010) 1.10
Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun (2003) 1.09
Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect Immun (2002) 1.08
Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol (2012) 1.07
FMS-like tyrosine kinase 3 ligand aggravates the lung inflammatory response to Streptococcus pneumoniae infection in mice: role of dendritic cells. J Immunol (2007) 1.06
Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine (2008) 1.06
Structural characterization of Streptococcus pneumoniae serotype 9A capsule polysaccharide reveals role of glycosyl 6-O-acetyltransferase wcjE in serotype 9V capsule biosynthesis and immunogenicity. J Biol Chem (2012) 1.05
Elucidation of structural and antigenic properties of pneumococcal serotype 11A, 11B, 11C, and 11F polysaccharide capsules. J Bacteriol (2011) 1.05
Influence of asthma status on serotype-specific pneumococcal antibody levels. Postgrad Med (2010) 1.05
A four-parameter logistic model for estimating titers of functional multiplexed pneumococcal opsonophagocytic killing assay. J Biopharm Stat (2008) 1.05
A new model of pneumococcal lipoteichoic acid structure resolves biochemical, biosynthetic, and serologic inconsistencies of the current model. J Bacteriol (2008) 1.05
Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci (2013) 1.04
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. J Infect Dis (2007) 1.03
Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother (2013) 1.03
The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis (2010) 1.02
Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution. Clin Infect Dis (2012) 1.01
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Cochlear pathology in human temporal bones with otitis media. Acta Otolaryngol (2010) 1.01
Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J Clin Microbiol (2003) 1.00
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun (2005) 1.00
Characterization of the dihydrolipoamide dehydrogenase from Streptococcus pneumoniae and its role in pneumococcal infection. Mol Microbiol (2002) 1.00
Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol (2010) 0.99
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 0.99
Effects of zinc deficiency and pneumococcal surface protein a immunization on zinc status and the risk of severe infection in mice. Infect Immun (2003) 0.99
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol (2010) 0.99
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae. Antimicrob Agents Chemother (2009) 0.98
Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine (2004) 0.98
Streptococcus pneumoniae serotype 9A isolates contain diverse mutations to wcjE that result in variable expression of serotype 9V-specific epitope. J Infect Dis (2011) 0.97
Streptococcus pneumoniae serotype 11D has a bispecific glycosyltransferase and expresses two different capsular polysaccharide repeating units. J Biol Chem (2013) 0.97
The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med (2013) 0.97
Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger. Clin Infect Dis (2012) 0.97
CCL5 modulates pneumococcal immunity and carriage. J Immunol (2006) 0.96
Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniae. Antimicrob Agents Chemother (2011) 0.95
The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol (2012) 0.95